Rekha N Rangarajan from 6808 Vista Ridge Dr E, Fort Worth, TX 76132, age 46, Phone: 8604298688

Resumes

Director, New Products Ideation, Dry Eye, Global Vision Care Franchise

view source

Location:

Tolland, CT

Industry:

Pharmaceuticals

Work:

Alcon, A Novartis Company
Director, New Products Ideation, Dry Eye, Global Vision Care Franchise
Novartis Feb 2016 - Jun 2018
Associate Technical Project Leader
Novartis Apr 2015 - Jan 2016
Fellow
Alcon, A Novartis Company Sep 1, 2008 - Mar 2015
Senior Scientist Ii and Principal Scientist
University of Connecticut May 2007 - Aug 2008
Post Doctoral Researcher

Education:

Stanford University 2014 - 2015
University of Connecticut 2000 - 2007
Doctorates, Doctor of Philosophy, Biochemistry University of Madras 1998 - 2000
Master of Science, Masters, Biochemistry University of Madras 1995 - 1998
Bachelors, Bachelor of Science, Zoology

Skills:

Protein Chemistry
Biochemistry
Molecular Biology
Nutrition
Nutraceuticals
Cell Culture
Pcr
Rt Pcr
Protein Engineering
Protein Expression
Protein Purification
Elisa
Bioassay
Microsoft Office
Blotting
Cell Viability Assays
Microplate Reader
Hplc
Glp
Pharmaceutical Industry
Chemistry
Clinical Development

Rekha Rangarajan

view source

Us Patents

Bacteriorhodopsin Protein Variants And Methods Of Use For Long Term Data Storage
view source
US Patent:

20090268511, Oct 29, 2009
Filed:

Jan 14, 2009
Appl. No.:

12/353282
Inventors:

Robert R. Birge - Coventry CT, US
Rekha Rangarajan - Fort Worth TX, US
Kristina Nicole McCleary - Cheshire CT, US
Assignee:

University of Connecticut - Farmington CT
International Classification:

G11C 13/04
C07K 14/195
US Classification:

365151, 530350
Abstract:

Bacteriorhodopsin protein variants and methods using the bacteriorhodopsin variants for performance in holographic and three-dimensional (3D) memory storage devices are described. The amino acid and chemical modifications of bacteriorhodopsin provided herein achieve greatly enhanced protein performance. The memory storage devices write, read and erase data proficiently. The bacteriorhodopsin protein variants are useful in optical memory storage and associative processor systems. Irradiation of the light-sensitive protein with light of known wavelength causes the protein to switch between different states. The variants enter the branched photocycle via a single or a two photon process and form the permanent ‘Q’ state more efficiently than the wild-type bacteriorhodopsin protein. This branching photocycle of the variants is exploited in the fabrication of 3D memory storage devices.

Ophthalmic Compositions With Improved Dessication Protection And Retention
view source
US Patent:

20130296264, Nov 7, 2013
Filed:

May 3, 2013
Appl. No.:

13/886788
Inventors:

Howard Allen Ketelson - Dallas TX, US
Elaine E. Campbell - Shelton CT, US
David L. Meadows - Colleyville TX, US
Rekha Rangarajan - Fort Worth TX, US
Assignee:

ALCON RESEARCH, LTD. - Fort Worth TX
International Classification:

A61K 31/736
A61K 31/728
US Classification:

514 54
Abstract:

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Protein-Based Photovoltaics And Methods Of Use
view source
US Patent:

20090229669, Sep 17, 2009
Filed:

Feb 4, 2009
Appl. No.:

12/365289
Inventors:

Robert R. Birge - Coventry CT, US
Rekha Rangarajan - Fort Worth TX, US
Assignee:

University of Connecticut - Farmington CT
International Classification:

H01L 31/04
H01L 31/18
C07K 14/195
US Classification:

136263, 438 1, 530408
Abstract:

Protein-based photovoltaic cells and the manufacture and use of protein-based photovoltaic cells are described. In one embodiment, bacteriorhodopsin from , which undergoes structural transitions when irradiated with a given wavelength of light, is used as the protein in the protein-based photovoltaic cells. In another embodiment, mutant bacteriorhodopsin from is used. Exposure of the protein to sunlight causes proton transfer across a membrane resulting in the generation of an electrical charge. The protein can be oriented and/or layered on a substrate and modified by mutation to enhance transmembrane proton transfer, covalent binding to a substrate and layering. The protein-based photovoltaic cells sequentially or simultaneously generate hydrogen gas from water or salt, which also can be harnessed to produce electricity.

Dissolvable Polymeric Eye Inserts With A Biodegradable Polymer And Method Of Using The Same
view source
US Patent:

20220323346, Oct 13, 2022
Filed:

Jun 23, 2022
Appl. No.:

17/808342
Inventors:

- Fribourg, CH
Rekha Rangarajan - Fort Worth TX, US
International Classification:

A61K 9/00
A61K 31/357
A61K 31/498
A61K 47/10
A61K 47/32
A61K 47/34
A61K 47/36
Abstract:

Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more mucoadhesive polymers polymers, a biodegradable polymer as well as softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. The biodegradable polymer containing eye insert may increase dissolution time on the ocular surface for longer lasting relief, may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.

Ophthalmic Compositions With Improved Dessication Protection And Retention
view source
US Patent:

20220273699, Sep 1, 2022
Filed:

May 19, 2022
Appl. No.:

17/664143
Inventors:

- Fribourg, CH
Howard Allen Ketelson - Dallas TX, US
Elaine E. Campbell - Shelton CT, US
David L. Meadows - Colleyville TX, US
Rekha Rangarajan - Fort Worth TX, US
International Classification:

A61K 31/736
A61K 9/00
A61K 47/02
A61K 47/10
A61K 47/26
A61K 47/36
A61K 47/32
A61K 31/728
Abstract:

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

Lipid-Based Ophthalmic Emulsion
view source
US Patent:

20210128468, May 6, 2021
Filed:

Jan 12, 2021
Appl. No.:

17/147007
Inventors:

- FRibourg, CH
James W. Davis - Falmouth ME, US
Rekha Rangarajan - Fort Worth TX, US
International Classification:

A61K 9/107
A61K 47/02
A61K 47/24
A61K 47/36
A61K 9/00
A61K 47/26
A61K 47/34
Abstract:

The present invention is directed to a lipid-based ophthalmic emulsion. The emulsion has an increased amount of a mucoadhesive galactomannan polymer that promotes a long-lasting protection against desiccation and moisture retention.

Ophthalmic Compositions With Improved Dessication Protection And Retention
view source
US Patent:

20210060056, Mar 4, 2021
Filed:

Oct 1, 2020
Appl. No.:

17/060343
Inventors:

- Fribourg, CH
Howard Allen Ketelson - Dallas TX, US
Elaine E. Campbell - Shelton CT, US
David L. Meadows - Colleyville TX, US
Rekha Rangarajan - Fort Worth TX, US
International Classification:

A61K 31/736
A61K 9/00
A61K 47/02
A61K 47/10
A61K 47/26
A61K 47/36
A61K 47/32
A61K 31/728
Abstract:

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the to compositions also comprise a borate compound.

Dissolvable Polymeric Eye Inserts And Method Of Using Same
view source
US Patent:

20200345544, Nov 5, 2020
Filed:

May 1, 2020
Appl. No.:

16/864894
Inventors:

- Fribourg, CH
Rekha Rangarajan - Fort Worth TX, US
Walter R. Laredo - Fort Worth TX, US
Stephen John Collins - Fort Worth TX, US
International Classification:

A61F 9/00
A61K 47/10
A61K 47/22
A61K 9/00
A61K 47/36
A61K 47/14
Abstract:

Polymeric eye inserts are provided that may be dissolvable when placed in the cul-de-sac of the eye. These inserts may contain one or more polymers as well as a softener/plasticizer so that, when inserted into the eye, they may absorb tears, and dissolve and slowly release lubricant into the tear film to lubricate and protect the ocular surface for an extended duration of time. Increased retention time on the ocular surface for longer lasting relief may reduce dosing frequency and patient burden typically associated with topical drop usage. These polymeric eye inserts also may include one or more pharmaceutically active agents.